Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 118-122

  Hirsch, Fred R ^a   Witta, Samir ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor Inhibitors; Fluorescence in situ hybridization; Lung cancer; Predictive markers

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 17144411518     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000155059.39733.9d     Document Type: Review

References (30)

1. Argiris A, Schiller JH. Can current treatments for advanced non-small-cell lung cancer be improved? JAMA 2004; 292:499-500.
2. Schiller JH, Harrington KM, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92-98.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
5. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22:3238-3247.
6. Shepherd F, et al. Erlotinib versus placebo in pretreated patients with advanced NSCLC [late breaking abstract]. American Soc Clin Oncol; New Orleans: 2004.
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807.
8. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41:S29-S42.
9. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2 (abstract no. LB-170). 94th Annual Meeting of the American Association for Cancer Research: Washington DC; July 2003: #1362.
10. Cappuzzo F, Gregore V, Rossi E, et al. Gefitinib in pretreated non-small cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003; 21:2658-2663.
11. Han S-W, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113:109-115.
12. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst (in press).
13. Cappuzzo F, Magrini E, Cereoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2004;96:1133-1141.
14. L858R non-small cell lung cancer cell line H 3255. Cancer Res 2004; 64:7241-7244.
15. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167.
16. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD 1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Molecular Cancer Therapeutics, 2004:465-471.
17. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosin kinase inhibitor ZD 1839 (Iressa) inhibits HER2-driven signaling and suppress the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61:7184-7188.
18. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor (EGFR) and HER2 gene amplification predict response to gefitinib therapy in advanced non-small cell lung cancer (NSCLC). Ann Oncol 2004; 15(suppl 3):166 (abstract 628).
19. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235:177-182.
20. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:29-39.
22. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
23. Janne P. Personal communication. 40th Annual Meeting of American Soc Clin Oncol; New Orleans: June 5-8 2004.
24. Lynch TJ, Lilienbaum R, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 22:(abstract 7084).
25. Stephens P, Hunter C, Bignell G, et al. Intragenic ERBB2 kinase mutations in tumors. Nature 2004; 431:525-526.
26. Perez-Soler R, Ling YH, Lia M, et al. Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCl in human cell lines. Proc Am Soc Clin Oncol 2003; 22:(abstract 762).
27. Hirsch FR, Franklin WA, Witta SE, et al. Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Proc Am Soc Clin Oncol 2004; 22:623(abstract 7027).
28. Witta SE, Helfrich B, Sugita M, et al. Expression of the E-cadherin inhibitory zinc finger transcription factors 6EF1/ZEB1 and SIP1/ZEB2 correlates with resistance to EGFR inhibitors. Proc Am Assoc Cancer Res 2004; 45:847(abstract 3671).
29. Zembutsu H, Ohnishi Y, Daigo Y, et al. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol 2003; 23:29-39.
30. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13:3029-3043.